Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
LEHIGH COUNTY EMPLOYEES' RETIREMENT SYSTEM v. NOVO NORDISK A/S et al
Case Number:
3:17-cv-00209
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Carella Byrne
- Gibbons PC
- Latham & Watkins
- Levi & Korsinsky
- Lite DePalma
- Roselli Griegel
- Seeger Weiss
Companies
Sectors & Industries:
-
May 24, 2022
Investors' Attys Seek $29M Cut Of Novo Nordisk Deal
Attorneys for investors in Danish pharmaceutical giant Novo Nordisk have requested nearly a third of a $100 million settlement that, if approved, would resolve claims the company hurt shareholders by failing to disclose "increasingly large kickbacks" it allegedly paid pharmacy benefit managers to get its products on lists of drugs recommended to providers.
-
September 24, 2021
Novo Nordisk To Pay $100M To Settle Investor Class Action
Novo Nordisk announced Friday that it has reached a $100 million settlement in an investor class action alleging the Danish pharmaceutical giant boasted about its finances while concealing a scheme to pay kickbacks to pharmacy benefit managers to get its insulin drugs on stores' recommended product lists.
-
January 31, 2020
Novo Nordisk Investors Win Cert. In Insulin Kickback Suit
A New Jersey federal judge on Friday granted certification to a class of Novo Nordisk investors in a suit alleging the Danish pharmaceutical giant misled shareholders about the driving forces behind its financial growth while concealing a scheme to pay kickbacks to pharmacy benefit managers in exchange for access to the insulin marketplace.
-
April 02, 2019
Novo Nordisk Investors Seek Cert. In Insulin Pricing Suit
Five retirement plans have pressed a New Jersey federal judge for class certification in their suit accusing Novo Nordisk of boasting about its finances while concealing a scheme to pay off pharmacy benefit managers to get its insulin drugs on stores' recommended product lists.
-
August 16, 2018
Novo Nordisk Can't Dodge Shareholder Suit In NJ
A New Jersey federal judge on Thursday refused to toss a putative class action accusing Novo Nordisk of misleading shareholders about its financial sustainability in the U.S. market, ruling that the investors had sufficiently alleged that the Danish insulin maker made materially misleading statements about its rebate program and the pricing pressures facing its drug Tresiba.